Latest MMED news and sentiment

J. Goldman & Co LP Takes Position in MiniMed Group Inc $MMED

J. Goldman & Co LP has acquired a new stake in MiniMed Group Inc (NASDAQ:MMED), purchasing over 830,000 shares valued at approximately $12.41 million during the second quarter. Other institutional investors, including Bank of New York Mellon Corp and BlackRock Inc., have also recently bought or increased their positions in the company. MiniMed Group's stock currently trades at $18.92, with analysts predicting a "Moderate Buy" rating and a consensus price target of $21.62.

MiniMed Group (NASDAQ:MMED) Stock Price Down 4% - Here's What Happened

MiniMed Group, Inc. SEC Filing (Aug 21, 2026)

This article reports on an SEC filing (Form ARS) by MiniMed Group, Inc. (MMED) on August 21, 2026. The filing was accepted by the SEC EDGAR system at 04:24 PM EST. The article provides company stock data, recent news, and other SEC filings for MiniMed Group.

Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge?

Two healthcare innovators, MiniMed Group, Inc. (NASDAQ:MMED) and Abbott Laboratories (NYSE:ABT), hit the spotlight this August with a milestone partnership. On August 17, MiniMed announced that its MiniMed Flex system is commercially shipping in the U.S., integrated with Abbott's Instinct continuous glucose sensor. This collaboration marks a major leap in diabetes tech, pairing MiniMed's smallest, only app-controlled automated insulin delivery system with Abbott's world's-smallest 15-day sensor. Driven by SmartGuard technology and Meal Detection automation, the setup holds 300 units of insulin

MiniMed (MMED) Quarter in Focus: The Bottom-Line Figure Trails Its Comparison in the Current Update; Price Move: Shares Finish 0.72% Higher in the Latest Reading - Post-Announcement Reaction

MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor

MiniMed Group, Inc. MMED recently announced that the MiniMed Flex system is now commercially shipping in the United States with Abbott Laboratories' Instinct sensor. The combination brings together the company's smallest and only app-controlled insulin pump with a sensor offering up to 15 days of wear. The expanded availability gives people with diabetes another option for managing their condition with a discreet, longer-wear sensor and automated insulin delivery technology. Per management, MiniMed Flex is intended to provide advanced diabetes technology with minimal day-to-day effort for user

MiniMed Launches Abbott's Instinct Sensors Across European Markets

MiniMed has commercially launched its MiniMed 780G and MiniMed Go automated insulin delivery systems integrated with Abbott Laboratories' Instinct and Instinct Go sensors across European markets. This expansion provides greater flexibility and choice for people with diabetes, enhancing MiniMed's competitive position in the growing diabetes technology market. The integration is expected to boost customer adoption and retention by offering broader sensor compatibility while maintaining proven clinical outcomes.

MiniMed Inc And Abbott Laboratories Begin Shipping MiniMed Flex System With Instinct Sensor In United States

MiniMed Inc. announced the commercial shipment of its MiniMed Flex system in the United States, featuring the Instinct sensor from Abbott Laboratories. This system offers individuals with diabetes an app-controlled insulin pump combined with the world's smallest sensor, providing up to 15 days of wear. It is FDA cleared for type 1 diabetes patients aged 7 and older and adults with insulin-requiring type 2 diabetes.

MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor

MiniMed Flex™ with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif., Aug. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced that the MiniMed Flex™ system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. For the first time, people with diabetes can use MiniMed's smallest and only app-controlled insulin pump with the world's smallest sensor, with up to 15 days of wear.1MiniMed Flex with Instinct sensor, made by Abbott

MiniMed Group Inc. (MMED) Stock Price | Live Quotes & Charts | NASDAQ

This article provides live quotes and charts for MiniMed Group Inc. (MMED) stock, showing its current price as $20.15 with no change. It also indicates that there is no analyst rating data or earnings information currently available for the company. The page promotes a stock trading bootcamp and free trade alerts.

MiniMed Poised to Roll Out New Innovations in Diabetes Devices but Has Yet to Dig a Moat

MiniMed, recently spun out from Medtronic, is focusing on innovation in diabetes device technology. The company, a leader in durable, tubed insulin pumps for Type 1 diabetes, faces increasing competition despite its historical market presence. An analyst note initiates coverage with a "no-moat" rating and a $15 fair value estimate.

MiniMed Group (Nasdaq:MMED) - Stock Analysis

This stock analysis report for MiniMed Group (Nasdaq:MMED) provides an overview of the company's financial health, future growth prospects, past performance, and valuation. It highlights recent news including the launch of new insulin pump systems, board changes, and financial results, noting the company is trading significantly below its estimated fair value but faces ongoing net losses. The article also touches on analyst expectations for the company to achieve profitability by 2027.

MiniMed Group (NASDAQ: MMED) says General Counsel Courtney Nelson Wills will step down

MiniMed Group (NASDAQ: MMED) announced that its Senior Vice President, General Counsel, and Corporate Secretary, Courtney Nelson Wills, will resign effective September 25, 2026. Ms. Wills notified the company on July 30, 2026, and her departure is due to personal reasons, as she has accepted a role outside the medical device industry, not due to any disagreement with MiniMed. The company is searching for a successor and emphasizes its commitment to maintaining strong legal and governance oversight during the 8-week transition period.

MiniMed Group Inc (NASDAQ:MMED) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Analysts have given MiniMed Group Inc (NASDAQ:MMED) a "Moderate Buy" consensus recommendation, with 13 buy ratings, two holds, and one sell from 16 firms. The average 12-month price target is $21.62, higher than the stock's opening price of $18.05. Despite mixed recent analyst actions including some price target cuts, UBS initiated coverage with a buy rating and a $25 target. The company reported quarterly revenue of $837 million, a 15.6% increase year-over-year, but missed analyst expectations for adjusted loss per share.